Role and clinical application of next-generation sequencing (NGS) for ovarian cancer.

about

Second primary cancer after primary peritoneal, epithelial ovarian, and fallopian tubal cancer: a retrospective study

P2860

Q57213867-7CBB13AE-4C32-48F7-8BEC-FA3C8E7A4505

P2860

Role and clinical application of next-generation sequencing (NGS) for ovarian cancer.

Item

http://www.wikidata.org/entity/Q42345758

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Role and clinical application of next-generation sequencing (NGS) for ovarian cancer.

@en

Role and clinical application of next-generation sequencing

@nl

type

Item

label

Role and clinical application of next-generation sequencing (NGS) for ovarian cancer.

@en

Role and clinical application of next-generation sequencing

@nl

prefLabel

Role and clinical application of next-generation sequencing (NGS) for ovarian cancer.

@en

Role and clinical application of next-generation sequencing

@nl

P1476

Role and clinical application of next-generation sequencing (NGS) for ovarian cancer

@en

P2093

Leslie M Randall

http://www.w3.org/2001/XMLSchema#string

Myong Cheol Lim

http://www.w3.org/2001/XMLSchema#string

P2860

Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing

Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas

Integrated genomic analyses of ovarian carcinoma

Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer.

Comparison of Clinical Outcomes of BRCA1/2 Pathologic Mutation, Variants of Unknown Significance, or Wild Type Epithelial Ovarian Cancer Patients

Germline and somatic mutations in homologous recombination genes among Chinese ovarian cancer patients detected using next-generation sequencing.

Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer.

Hereditary ovarian cancer: not only BRCA 1 and 2 genes.

Position statements on genetic test for peritoneal, ovarian, and fallopian tubal cancers: Korean Society of Gynecologic Oncology (KSGO).

Hereditary ovarian cancer: beyond the usual suspects.

P304

e51

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

editorial

P356

10.3802/JGO.2017.28.E51

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Myong Cheol Lim

Leslie M Randall

P577

2017-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28541638

http://www.w3.org/2001/XMLSchema#string

P921

ovarian cancer

P932

5447149

http://www.w3.org/2001/XMLSchema#string

Role and clinical application of next-generation sequencing (NGS) for ovarian cancer.

about

P2860

P2860

Role and clinical application of next-generation sequencing (NGS) for ovarian cancer.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921

P932